lifestyle.marketresearchjournals.com

Author: Femasys Inc.

Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

April 16, 2026
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

April 1, 2026
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

April 1, 2026
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

March 18, 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

February 23, 2026
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

February 10, 2026